- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Do | Glenmark Pharma set to launch Ropivacaine Hydrochloride Injection in US | 3 | capitalmarket.com | ||
| 28.09. | Glenmark, Granules, Zydus and others recall medicines in US over quality issues: USFDA | 2 | ZEE Business | ||
| 26.09. | Fierce Pharma Asia-Celltrion's Lilly plant buy; Rexulti's PTSD snub; Glenmark, Hengrui's ADC deal | 5 | FiercePharma | ||
| 25.09. | China's Hengrui Rises After Granting India's Glenmark Cancer Drug Rights in Up to USD1.1 Billion Deal | 2 | Yicai Global | ||
| 25.09. | Stock Alert: Glenmark Pharmaceuticals, Lupin, NTPC, Pipavav Port, Newgen | 2 | capitalmarket.com | ||
| 24.09. | In potential $1.1B deal, Glenmark grabs certain rights to Hengrui's ADC rival to Enhertu | 3 | FiercePharma | ||
| GLENMARK PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 15.09. | Dividendenbekanntmachungen (15.09.2025) | 13.207 | wallstreetONLINE (Dividenden) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A&W FOOD SERVICES OF CANADA INC CA0002251027 0,48 CAD 0,2954 EUR ALLEGION PLC IE00BFRT3W74 0,51 USD 0,4345 EUR ALTRIA GROUP INC US02209S1033 1... ► Artikel lesen | |
| 08.09. | Glenmark Expands Phase 3 Study of Envafolimab to Multiple Regions | 2 | Mexico Business News | ||
| 05.09. | Glenmark Pharmaceuticals: Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer | 310 | PR Newswire | DCGI grants No Objection Certificate to commence enrollment in India
Clinical Trial Applications underway in Russia, Brazil, and Mexico
MUMBAI, India, Sept. 5, 2025 /PRNewswire/... ► Artikel lesen | |
| 05.09. | Glenmark Pharmaceuticals: Glenmark Initiates a Multi-Country Phase 3 Clinical Trial for Envafolimab in Resectable Stage III Non-Small Cell Lung Cancer | 370 | PR Newswire | DCGI grants No Objection Certificate to commence enrollment in India
Clinical Trial Applications underway in Russia, Brazil, and Mexico
MUMBAI, India, Sept. 5, 2025 /PRNewswire/... ► Artikel lesen | |
| 02.09. | Glenmark Pharma's US arm to launch Eribulin Mesylate injection in the US market | 2 | capitalmarket.com | ||
| 20.08. | Alembic, Sun and Glenmark issue US drug recalls due to the presence of carcinogens or foreign matter | 5 | FiercePharma | ||
| 19.08. | Glenmark Pharma's US arm to launch Micafungin injection in the US market | 2 | capitalmarket.com | ||
| 18.08. | Glenmark Pharma shares tumble despite market-wide rally post-Q1 results | 2 | ZEE Business | ||
| 18.08. | Glenmark Pharma, HDFC Bank among 10 stocks that showed RSI Trending Up on August 14 | 3 | Times of India | ||
| 06.08. | Glenmark Pharmaceuticals Subsidiary Reaches $37.75 Million Settlement in US Antitrust Case | 3 | CPI | ||
| 28.07. | Glenmark Pharmaceuticals Ltd spurts 1.22%, up for third straight session | 3 | capitalmarket.com | ||
| 18.07. | Glenmark stock downgraded to Sell by ICICI Securities despite price target hike | 6 | Investing.com | ||
| 18.07. | ICICI Securities stuft Glenmark-Aktie trotz Kurszielerhöhung auf 'Verkaufen' herab | 3 | Investing.com Deutsch | ||
| 16.07. | Glenmark Pharmaceuticals Ltd up for five straight sessions | 2 | capitalmarket.com |
1 2 3 4 Weiter >>
65 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SINOPHARM | 2,129 | -0,61 % | Sinopharm Group Co. Ltd. Nine Months Sales Decline | ||
| CSPC PHARMA | 0,862 | +1,53 % | CSPC PHARMA (01093): UNAUDITED FINANCIAL INFORMATION OF CSPC INNOVATION PHARMACEUTICAL CO., LTD. FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025 | ||
| WUXI BIOLOGICS | 4,100 | +1,32 % | WuXi Biologics-Aktie leicht im Plus (4,441 €) | Das Wertpapier von WuXi Biologics notiert heute fester. Das Papier kostete zuletzt 4,44 Euro. Ein Preisanstieg in Höhe von 17 Cent erfreut derzeit die Aktionäre von WuXi Biologics. Zur Stunde kostet... ► Artikel lesen | |
| SHANGHAI FOSUN PHARMACEUTICAL | 2,502 | -1,42 % | Fangzhou Inc.: Fangzhou and Fosun Pharma Forge Strategic Alliance to Deliver AI-Powered Psoriasis Management | SHANGHAI, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Fangzhou Inc. ("Fangzhou" or the "Company") (HKEX: 06086), a leader in AI-driven Internet healthcare solutions, and Shanghai Fosun Pharmaceutical (Group)... ► Artikel lesen | |
| GEDEON RICHTER | 27,000 | +1,35 % | Gedeon Richter Plc.: Long-term Commitment to Treating Endometriosis and Improving Women's Quality of Life - Gedeon Richter at the World Congress on Endometriosis | SYDNEY, May 28, 2025 /PRNewswire/ --
Gedeon Richter had a strong presence at the World Congress of Endometriosis held this year in Sydney, Australia between 21-24 May 2025. As a Platinum... ► Artikel lesen | |
| DR REDDYS | 12,000 | -3,23 % | Dr. Reddy's Laboratories Q2 Profit Rises | NEW DELHI (dpa-AFX) - Dr. Reddy's Laboratories Ltd. (ROY) reported, under IFRS standards, that its second quarter profit attributable to equity holders of the parent company increased to INR... ► Artikel lesen | |
| ASPEN PHARMACARE | 5,150 | +3,00 % | ASPEN PHARMACARE HOLDINGS LIMITED - Availability of Integrated Report, B-BBEE Verification Certificate and Further Notice of Annual General Meeting | ||
| SHANGHAI PHARMACEUTICALS | 1,330 | 0,00 % | Dividendenbekanntmachungen (16.07.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ACERINOX SA ES0132105018 - 0,31 EUR ALAMO GROUP INC US0113111076 0,3 USD 0,2586 EUR APOGEE ENTERPRISES INC US0375981091 0,26 USD 0... ► Artikel lesen | |
| LUYE PHARMA | 0,342 | 0,00 % | LUYE PHARMA (02186): INTERIM REPORT 2025 | ||
| SIHUAN PHARMACEUTICAL HOLDINGS GROUP | 0,158 | 0,00 % | SIHUAN PHARM (00460): VOLUNTARY ANNOUNCEMENT - NG-350A GRANTED FAST TRACK DESIGNATION BY THE U.S. FDA | ||
| HANSOH PHARMACEUTICAL | 3,860 | +1,05 % | HANSOH PHARMA (03692): VOLUNTARY ANNOUNCEMENT - NEW DRUG APPLICATION OF HS-10365 CAPSULES WAS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION | ||
| CHINA RESOURCES PHARMACEUTICAL | 0,565 | +2,73 % | CHINARES PHARMA (03320): ANNOUNCEMENT UNAUDITED FINANCIAL RESULTS OF CR BOYA BIO-PHARMACEUTICAL FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2025 | ||
| CHINA SHINEWAY PHARMACEUTICAL GROUP | 0,900 | -1,10 % | Dividendenbekanntmachungen (09.09.2025) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ALUMINUM CORPORATION OF CHINA LTD CNE1000001T8 0,1348 HKD 0,0147 EUR AMEREN CORPORATION US0236081024 0,71 USD 0,6037 EUR ANHUI... ► Artikel lesen | |
| KALBE FARMA | 0,061 | -3,20 % | Kalbe Farma profit rises 10.63%, shares react positively: The shares of this Indeks52 constituent climb 3.25% ... | ||
| YICHANG HEC CHANGJIANG PHARMACEUTICAL | - | - | HEC CJ PHARM (01558): JOINT ANNOUNCEMENT UPDATE REGARDING CONDITIONAL PRIVATISATION OF YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD. BY SUNSHINE LAKE ... |
GLENMARK PHARMACEUTICALS LTD gehört der Branche Pharma an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu GLENMARK PHARMACEUTICALS LTD finden Sie auf Wallstreet Online.